Get in touch
Get in touch
Ambrosia Biosciences

World-class chemistry, best in-class therapeutics

Get in touch
thumb
press
Science Magazine: Companies seek a second obesity treatment revolution – in pill form
image
Overview

Ambrosia Biosciences Inc. is a drug discovery company developing orally delivered, small molecule-based therapies for obesity and other metabolic disorders.

Who we are

Meet the team

Together, we are united in our goal to deliver safe, effective, and affordable small molecule drugs that transform lives globally.
thumb

Nick Traggis

Founder and Chief Executive Officer

thumb

John Mayer, PhD

Founder and Chief Scientific Officer

thumb

Faraz Naqvi, MD

Founder and Medical Director

thumb

Patrice Lee, PhD

Vice President, Research & Development, Head of Pharmacology

thumb

Andrea Flynn, PhD

Chief Business Officer

thumb

Ben Carver

General Counsel

thumb

Kenny Edwards

Vice President, Finance

thumb

Erik Hicken, PhD

Vice President, Head of Chemistry

thumb

Matthew Martinson

Vice President, Operations

thumb

Kyle Lefkoff

Founder and Chairman

thumb

Nick Traggis

Founder and CEO

thumb

David Snitman, PhD

Founder and Director

thumb

William Marshall, PhD

Founder and Director

thumb

John Orwin

Founder and Director

thumb

Jason Haddock

Director

thumb

John Mayer, PhD

Scientific Advisory Board Chairman

thumb

Richard DiMarchi, PhD

Scientific Advisory Board

thumb

Thomas Hughes, PhD

Scientific Advisory Board

thumb

Nick Saccomano, PhD

Strategic Advisor

thumb

Kieran Chacko, PhD

Strategic Advisor

Our strategic network

Investors

We partner with seasoned biotech investors and industry partners who share our purpose, leveraging their expertise to drive forward our drug discovery programs.
thumb
//01.

BVF Partners

Visit BVF Partners

thumb
//02.

Boulder Ventures

Visit Boulder Ventures

thumb
//03.

Merck

Visit Merck

Press

Newsroom

News

Science Magazine: Companies seek a second obesity treatment revolution – in pill form

April 15, 2025
thumb
Press

Ambrosia Biosciences Further Strengthens Board of Directors with Appointment of Jason Haddock

February 19, 2025
thumb
Press

Ambrosia Biosciences Announces $25MM Series A Financing, Including Strategic Investment by Merck

December 10, 2024
thumb
News

Endpoints News: After Pfizer layoffs, Array chemists regather at next-gen obesity biotech Ambrosia Biosciences

August 21, 2024
thumb
Press

Ambrosia Biosciences Announces Series A Financing

August 20, 2024
thumb